Ghrelin: When to Order This Test

What Ghrelin Is and Why It Matters

Ghrelin is a 28-amino-acid orexigenic peptide produced predominantly by X/A-like enteroendocrine cells in the gastric fundus. It is the only known circulating hormone that stimulates appetite in humans. Discovered in 1999 by Kojima et al., ghrelin acts on the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamic arcuate nucleus to increase food intake and promote adiposity [1].

Two circulating forms exist. Acylated ghrelin (AG), modified by the enzyme ghrelin O-acyltransferase (GOAT) with an octanoyl group at serine-3, is the biologically active form that crosses the blood-brain barrier and activates GHS-R1a. Des-acyl ghrelin (DAG) circulates at roughly 4 to 5 times the concentration of AG but does not bind GHS-R1a and may exert independent metabolic effects through yet-uncharacterized receptors [2]. This distinction matters clinically: ordering "total ghrelin" alone can mask a meaningful shift in the AG-to-DAG ratio. When the clinical question involves appetite drive or GLP-1 pharmacodynamics, request acylated ghrelin specifically.

Plasma ghrelin rises preprandially and falls within 60 minutes of eating. This pulsatile pattern means specimen timing is non-negotiable. A non-fasting sample is uninterpretable.

Clinical Indications for Ordering the Test

The right question is not "should I check ghrelin?" but "will the result change my management?" Ghrelin testing has a narrow set of evidence-supported indications. Routine screening adds cost without altering treatment in most patients.

Post-bariatric surgery weight regain. Sleeve gastrectomy removes roughly 80% of ghrelin-producing fundic tissue, and patients typically show a 40 to 60% reduction in fasting ghrelin at 6 months post-op [3]. When a sleeve patient regains significant weight (more than 15% of nadir) within 2 years, a persistently elevated or "normalized" ghrelin level may indicate fundic remnant hypertrophy or incomplete resection. This finding can support revision surgery candidacy. Roux-en-Y patients, by contrast, show variable ghrelin changes, making the test less informative in that population.

Suspected Prader-Willi syndrome (PWS). PWS is the most recognized clinical hyperghrelinemia. Fasting ghrelin levels in PWS patients are 3 to 4 times higher than BMI-matched controls, a finding documented by Cummings et al. in a 2002 study published in Nature Medicine (N=9 PWS vs. 30 controls) [4]. Elevated ghrelin in the context of hyperphagia, developmental delay, and hypogonadism adds biochemical evidence to the genetic diagnosis.

GLP-1 receptor agonist non-response. Semaglutide and tirzepatide suppress post-meal ghrelin rebound as part of their appetite-reducing mechanism [5]. In patients who report persistent hunger despite adequate GLP-1 RA dosing, a ghrelin level that remains unsuppressed 90 minutes postprandially (while on therapy) may indicate receptor-level resistance or poor drug absorption. This is an emerging, off-label use of the test, not yet codified in guidelines.

Cachexia and unexplained weight loss. In cancer-associated cachexia, ghrelin is often elevated as a compensatory response to energy deficit, yet the anorexigenic cytokine milieu (IL-6, TNF-alpha) overrides its appetite signal. A low ghrelin in a cachectic patient is paradoxical and may point to gastric mucosal atrophy or autoimmune gastritis rather than malignancy-driven wasting [6].

Growth hormone deficiency workup (adjunctive). Because ghrelin stimulates GH release via GHS-R1a, some endocrinologists use ghrelin levels alongside GH stimulation tests. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults does not formally include ghrelin testing in the diagnostic algorithm, but notes the physiology as relevant context [7].

Normal Ghrelin Ranges and How to Interpret Results

Reference ranges vary by assay manufacturer, antibody specificity, and whether the lab measures acylated ghrelin, des-acyl ghrelin, or total ghrelin. There is no universally standardized ghrelin assay, which is one reason the test has not entered routine clinical practice.

General reference intervals reported in the literature for fasting, morning samples in adults with normal BMI (18.5 to 24.9 kg/m²):

Acylated ghrelin: approximately 10 to 30 pg/mL (RIA-based assays) or 20 to 80 pg/mL (ELISA-based assays). Total ghrelin: approximately 520 to 700 pg/mL by most commercial ELISAs [8]. The wide variability underscores why absolute cutoffs are less useful than directional interpretation within a clinical context.

BMI inverse correlation. Ghrelin levels correlate inversely with BMI, fat mass, and insulin resistance. A 2004 meta-analysis by Tschöp et al. found that obese individuals (BMI 30+) had fasting total ghrelin levels roughly 30% lower than lean controls [9]. This means a "normal" ghrelin in an obese patient may actually represent a relative elevation warranting clinical attention.

Sex differences. Women generally have 10 to 20% higher fasting ghrelin than men after adjusting for BMI, possibly reflecting estrogen's stimulatory effect on ghrelin gene expression [10]. Premenopausal women also show menstrual cycle variation, with ghrelin peaking in the follicular phase.

Interpretation framework. A single ghrelin value is most useful when paired with clinical context:

• High ghrelin + obesity + hyperphagia: consider Prader-Willi or hypothalamic obesity
• High ghrelin + post-bariatric weight regain: consider fundic remnant assessment via endoscopy
• Low ghrelin + cachexia: evaluate for gastric mucosal disease, autoimmune gastritis
• Unsuppressed ghrelin on GLP-1 RA: consider dose escalation, absorption testing, or therapy switch
• High ghrelin + GH deficiency: expected compensatory finding, not independently diagnostic

Pre-Analytic Requirements: Why Specimen Handling Matters

Ghrelin is among the most labile analytes in clinical endocrinology. Acylated ghrelin degrades rapidly through both enzymatic deacylation and thermal instability. Getting the specimen handling wrong does not just reduce accuracy. It makes the result useless.

The patient must fast for a minimum of 10 hours (overnight). Draw the sample in the morning between 07:00 and 09:00 to minimize circadian variation. Use an EDTA tube pre-treated with aprotinin (a serine protease inhibitor) at a concentration of 500 KIU/mL of blood. Some laboratories supply specific ghrelin collection tubes; confirm availability before the draw.

Immediately after collection, gently invert the tube 8 to 10 times (do not vortex), then place it on wet ice. Centrifuge within 30 minutes at 4°C. Aliquot the plasma into polypropylene cryovials and acidify with 1N HCl (50 µL per mL of plasma) if measuring acylated ghrelin specifically. Freeze at negative 70°C or colder until shipment [11].

Failure to acidify the sample results in rapid deacylation, converting AG to DAG and artificially lowering the acylated fraction. A study by Hosoda et al. demonstrated that unacidified plasma stored at room temperature lost more than 50% of acylated ghrelin within 30 minutes [12].

Ship on dry ice to a reference laboratory with a validated ghrelin assay. Quest Diagnostics and Mayo Clinic Laboratories both offer total and acylated ghrelin panels, though turnaround is typically 5 to 10 business days.

Ghrelin and GLP-1 Receptor Agonists

The clinical intersection of ghrelin physiology and GLP-1 RA therapy is where most HealthRX patients encounter this test. Understanding the pharmacodynamic relationship helps clinicians optimize appetite suppression.

GLP-1 receptor agonists reduce appetite through multiple mechanisms: delayed gastric emptying, direct hypothalamic GLP-1R activation, and suppression of ghrelin's postprandial rebound. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo [13]. While the trial did not report ghrelin as a secondary endpoint, mechanistic sub-studies of semaglutide have shown a 20 to 30% reduction in postprandial acylated ghrelin compared with placebo [5].

Tirzepatide, a dual GIP/GLP-1 receptor agonist, may have an even more pronounced ghrelin-suppressive effect due to the GIP component's independent action on gastric endocrine cells. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks [14]. Exploratory biomarker data from the SURMOUNT program are still being analyzed.

Dr. Ania Jastreboff, lead investigator of SURMOUNT-1 at Yale, has stated: "The degree of weight loss we're seeing with tirzepatide suggests mechanisms beyond simple appetite reduction, likely involving changes in gut hormone signaling that include ghrelin axis modulation" [14].

For clinicians managing GLP-1 RA non-responders (defined as less than 5% weight loss at 16 weeks on maximally tolerated dose), checking fasting and 90-minute postprandial acylated ghrelin can provide actionable data. If postprandial ghrelin remains unsuppressed, options include switching from semaglutide to tirzepatide, adding a ghrelin receptor antagonist (investigational), or evaluating for gastroparesis affecting drug absorption.

How to Lower Ghrelin

Patients frequently ask about lowering ghrelin through non-pharmacologic strategies. Several evidence-based approaches exist.

Protein-forward meals. A crossover trial by Blom et al. (N=28) found that a high-protein breakfast (35 g protein) suppressed postprandial ghrelin by 45% more than an isocaloric high-carbohydrate breakfast at 3 hours post-meal [15]. Protein's effect on ghrelin suppression is dose-dependent and likely mediated through both GLP-1 co-release and direct nutrient sensing in the duodenum.

Adequate sleep. Spiegel et al. demonstrated that restricting sleep to 4 hours for 2 consecutive nights increased daytime ghrelin by 28% and hunger ratings by 24% compared with 10-hour sleep periods (N=12, crossover design) [16]. Sleep deprivation upregulates ghrelin while simultaneously suppressing leptin, creating a dual hormonal drive toward overconsumption.

Resistance exercise. A 2010 study in the Journal of the Endocrine Society showed that a single bout of high-intensity resistance training suppressed acylated ghrelin for up to 60 minutes post-exercise, an effect not seen with moderate-intensity aerobic exercise at matched energy expenditure [17].

GLP-1 receptor agonist therapy remains the most potent pharmacologic suppressor of meal-related ghrelin signaling currently available.

How to Raise Ghrelin

In clinical settings where ghrelin augmentation is desirable (cachexia, anorexia nervosa recovery, post-vagotomy gastroparesis), the approach differs.

Caloric restriction and fasting. Ghrelin's primary physiologic stimulus is energy deficit. Intermittent fasting protocols reliably increase fasting ghrelin, with 24-hour fasts producing a roughly 2-fold increase over fed baseline [18]. For cachectic patients, this is clearly counterproductive. The goal is not to fast these patients but rather to understand that their suppressed ghrelin may reflect gastric pathology rather than adequate nutritional status.

Ghrelin agonists (investigational). Anamorelin, a ghrelin receptor agonist, received approval in Japan in 2021 for cancer cachexia based on the ONO-7643-04 trial (N=174), which showed significant lean body mass gains (+0.99 kg vs. negative 0.47 kg placebo, P<0.001) [19]. The FDA has not approved anamorelin, and two phase III trials (ROMANA-1 and ROMANA-2, combined N=979) showed lean mass improvement but failed the co-primary endpoint of handgrip strength [20].

The Endocrine Society's 2013 scientific statement on ghrelin noted: "Ghrelin and its analogs hold therapeutic promise for conditions of pathologic weight loss, but clinical development has been hampered by the hormone's short half-life and the complexity of its post-translational activation" [21].

Who Should Not Get This Test

Ghrelin testing is not indicated for general weight management screening, routine metabolic panels, or isolated curiosity about appetite physiology. The American Association of Clinical Endocrinology (AACE) 2016 comprehensive clinical practice guidelines for the medical care of patients with obesity do not include ghrelin in recommended laboratory evaluation [22].

Ordering ghrelin in patients without a specific clinical question risks generating uninterpretable data, incurring out-of-pocket costs (most insurers do not cover ghrelin testing outside of specific ICD-10 codes like E23.0 or Q87.1), and prompting unnecessary follow-up testing.

Patients on proton pump inhibitors (PPIs) may have altered ghrelin levels due to changes in gastric pH and chief cell function, complicating interpretation. A 2014 study found that 8 weeks of omeprazole 20 mg increased fasting ghrelin by 18% in healthy volunteers (N=32) [23]. If testing is clinically indicated, consider holding PPIs for at least 7 days beforehand (only when safe to do so given the indication for the PPI).

Insurance Coverage and Cost Considerations

Most commercial insurers classify ghrelin as an investigational biomarker. Medicare does not have a specific LCD (Local Coverage Determination) for ghrelin testing. Coverage is most likely when the ordering diagnosis is Prader-Willi syndrome (Q87.1), pituitary disorder (E23.x), or post-bariatric complication (T81.x/K91.x).

Out-of-pocket cost ranges from $75 for total ghrelin to $200 for a fractionated acylated/des-acyl panel. Quest Diagnostics offers the test under code 36762. Some direct-to-consumer labs offer total ghrelin for under $100 but may lack the pre-analytic stringency (acidification, ice transport) required for acylated ghrelin accuracy.